FBIO earnings analysis
What we found in FBIO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Fortress reported second-quarter revenue of $18.7 million, up 14% year over year, but diluted EPS declined to a loss of $0.08 from $0.45 in the prior-year quarter. Operating losses and R&D spending improved materially, and cash reached $196.6 million, with management indicating liquidity for at least the next 12 months. The outlook remains mixed because the company continues to incur losses, has $39.6 million of debt and $16.0 million of undeclared preferred dividends, while generic competition and Emrosi litigation add commercial risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew 14% year over year
- Second-quarter revenue was $18.7 million, up 14% year over year from $16.4 million. Revenue also increased from $16.0 million in the prior quarter.
- Operating loss narrowed materially
- Six-month operating loss improved to approximately $17.7 million from $58.8 million in the comparable 2025 period, a $41.1 million reduction.
- R&D spending fell sharply
- Six-month R&D expense declined to approximately $1.3 million from $12.1 million year over year, a reduction of $10.8 million.
- Cash balance strengthened
- Cash and cash equivalents increased to $196.6 million at quarter-end, providing substantial liquidity relative to the company’s stated minimum liquidity covenant of $2.0 million.
- Liquidity outlook remains adequate
- Management stated that current cash and cash equivalents should fund operations for at least 12 months from the August 13, 2026 filing date.
- Controls remained effective
- Disclosure controls and procedures were concluded effective as of June 30, 2026, and no material change in internal control over financial reporting occurred during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Quarterly earnings returned to a loss
- Diluted EPS was a loss of $0.08 versus diluted EPS of $0.45 in the prior-year quarter, reversing the prior-year quarterly profit and indicating continued earnings volatility.
- Debt and covenant exposure
- Debt outstanding, net of discount, was $39.6 million at June 30, 2026. The Oaktree agreement requires minimum liquidity of $2.0 million, and a covenant breach could trigger an event of default.
- Persistent losses and accumulated deficit
- Accumulated deficit was approximately $624.1 million at June 30, 2026, while the company reported operating losses of $17.7 million for the six months ended June 30, 2026. Management expects continued expenditures and operating costs and has not established a path to sustained profitability.
- Preferred dividend arrears restrict financing
- Series A Preferred Stock dividends remain paused at $0.1953125 per share monthly, deferring approximately $0.7 million in cash payments each month; undeclared cumulative dividends reached approximately $16.0 million at June 30, 2026. The pause also prevents use of new Form S-3 registration statements until specified conditions are met.
- Generic competition threatens revenue
- Five marketed products—Accutane, Targadox, Exelderm, Eurax and Luxamend—do not have patent protection or are not eligible for patent protection. Generic competition could reduce sales and operating income.
- Emrosi faces generic litigation
- Journey’s Emrosi patent litigation against Lupin triggered a stay of FDA approval of Lupin’s ANDA for up to 30 months. The challenged Journey patents expire in January 2039, but an adverse outcome could affect the product’s commercial prospects.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.08
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the 10-Q. Management stated that current cash and cash equivalents are expected to fund operations in the normal course for at least the next 12 months from filing.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 14, 2026
- Fortress Biotech reported a challenging Q1 2026, with revenues of $16.0 million, down 45% sequentially and missing estimates by 44.8%. The company recorded a net income of $110.4 million, influenced by the sale of a PRV…
- 10-K · March 31, 2026
- Fortress Biotech, Inc. reported significant growth with 2025 net revenue of $63.3 million, up 10.7% from $57.7 million in 2024, largely driven by new product launches including Emrosi. The company faced challenges,…
- 10-Q · November 14, 2025
- Fortress Biotech, Inc. reported Q3 2025 earnings with net revenue of $17.6 million, representing a 20.5% increase from $14.6 million in Q3 2024. The company experienced a significant turnaround in net income, achieving…
- 10-Q · August 14, 2025
- Fortress Biotech, Inc. reported a positive trend in Q2 2025, with revenue increasing to $16.4 million, a 10.9% rise from $14.9 million in Q2 2024. Despite this revenue growth, the company reported a diluted EPS of…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing FBIO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever